GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that an abstract ...
Scientists at the Francis Crick Institute have developed a new cancer therapy that halts tumour growth without harming healthy cells, now entering human trials.
Immutep Limited has announced promising results from its INSIGHT-003 trial, presented at the ESMO Congress 2025, showcasing a novel combination of eftilagimod alfa (efti) with KEYTRUDA and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback